Compare Stocks: COYA, CCCC, RZLT, and LRMR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCCC C4 Therapeutics	$3.41 -1.2%	$3.78	$1.69 ▼ $5.17	$419.53M	2.94	2.63 million shs	1.76 million shs
COYA Coya Therapeutics	$4.76 +6.7%	$4.62	$3.71 ▼ $7.75	$111.67M	0.61	181,943 shs	221,477 shs
LRMR Larimar Therapeutics	$3.80 -3.3%	$3.99	$2.71 ▼ $6.42	$394.74M	0.74	2.58 million shs	1.20 million shs
RZLT Rezolute	$3.95 -0.8%	$4.67	$1.07 ▼ $11.46	$380.35M	0.6	2.25 million shs	1.83 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCCC C4 Therapeutics	+0.58%	+0.29%	-19.01%	-16.46%	+1.17%
COYA Coya Therapeutics	-4.09%	-3.25%	-4.50%	-9.35%	-21.34%
LRMR Larimar Therapeutics	+0.51%	+1.55%	-9.03%	+8.03%	-1.75%
RZLT Rezolute	-4.10%	-1.97%	-14.96%	-20.72%	-48.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCCC C4 Therapeutics	$3.41 -1.2%	$3.78	$1.69 ▼ $5.17	$419.53M	2.94	2.63 million shs	1.76 million shs
COYA Coya Therapeutics	$4.76 +6.7%	$4.62	$3.71 ▼ $7.75	$111.67M	0.61	181,943 shs	221,477 shs
LRMR Larimar Therapeutics	$3.80 -3.3%	$3.99	$2.71 ▼ $6.42	$394.74M	0.74	2.58 million shs	1.20 million shs
RZLT Rezolute	$3.95 -0.8%	$4.67	$1.07 ▼ $11.46	$380.35M	0.6	2.25 million shs	1.83 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCCC C4 Therapeutics	+0.58%	+0.29%	-19.01%	-16.46%	+1.17%
COYA Coya Therapeutics	-4.09%	-3.25%	-4.50%	-9.35%	-21.34%
LRMR Larimar Therapeutics	+0.51%	+1.55%	-9.03%	+8.03%	-1.75%
RZLT Rezolute	-4.10%	-1.97%	-14.96%	-20.72%	-48.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CCCC C4 Therapeutics	2.60	Moderate Buy	$7.67	124.83% Upside
COYA Coya Therapeutics	2.71	Moderate Buy	$15.33	222.13% Upside
LRMR Larimar Therapeutics	3.00	Buy	$11.86	212.03% Upside
RZLT Rezolute	2.58	Moderate Buy	$9.38	137.34% Upside

Current Analyst Ratings Breakdown

Latest COYA, CCCC, RZLT, and LRMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/15/2026	COYA Coya Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00
9/14/2026	LRMR Larimar Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$13.00
8/24/2026	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/24/2026	COYA Coya Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
8/14/2026	RZLT Rezolute	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00
8/5/2026	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$12.00 ➝ $11.00
7/30/2026	RZLT Rezolute	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	CCCC C4 Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	COYA Coya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	LRMR Larimar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CCCC C4 Therapeutics	$35.95M	11.67	N/A	N/A	$2.65 per share	1.29
COYA Coya Therapeutics	$7.95M	14.05	N/A	N/A	$2.06 per share	2.31
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$0.94 per share	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	$1.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CCCC C4 Therapeutics	-$104.99M	-$1.00	N/A	N/A	N/A	-289.44%	-45.45%	-30.90%	11/5/2026 (Estimated)
COYA Coya Therapeutics	-$21.23M	-$1.07	N/A	N/A	N/A	-270.22%	-52.05%	-46.34%	11/11/2026 (Estimated)
LRMR Larimar Therapeutics	-$165.67M	-$1.95	N/A	N/A	N/A	N/A	-137.39%	-97.65%	11/5/2026 (Estimated)
RZLT Rezolute	-$74.41M	-$0.82	N/A	N/A	N/A	N/A	-58.82%	-54.48%	11/5/2026 (Estimated)

Latest COYA, CCCC, RZLT, and LRMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	CCCC C4 Therapeutics	-$0.2264	-$0.18	+$0.0464	-$0.18	$4.00 million	$6.64 million
8/11/2026	Q2 2026	COYA Coya Therapeutics	-$0.3457	-$0.28	+$0.0657	-$0.28	$0.13 million	$0.24 million
8/4/2026	Q2 2026	LRMR Larimar Therapeutics	-$0.3815	-$0.30	+$0.0815	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CCCC C4 Therapeutics	N/A	5.45	5.45
COYA Coya Therapeutics	N/A	13.40	13.40
LRMR Larimar Therapeutics	N/A	4.70	4.70
RZLT Rezolute	N/A	15.84	15.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CCCC C4 Therapeutics	78.81%
COYA Coya Therapeutics	39.75%
LRMR Larimar Therapeutics	91.92%
RZLT Rezolute	82.97%

Insider Ownership

Company	Insider Ownership
CCCC C4 Therapeutics	5.60%
COYA Coya Therapeutics	6.10%
LRMR Larimar Therapeutics	4.00%
RZLT Rezolute	14.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CCCC C4 Therapeutics	104	123.03 million	116.14 million	Optionable
COYA Coya Therapeutics	8	23.46 million	22.03 million	Not Optionable
LRMR Larimar Therapeutics	71	103.88 million	99.73 million	Optionable
RZLT Rezolute	71	96.29 million	82.06 million	Optionable

COYA, CCCC, RZLT, and LRMR Headlines

Recent News About These Companies

Rezolute, Inc. (NASDAQ:RZLT) Receives $9.38 Average Price Target from Analysts

September 16 at 4:00 AM | defenseworld.netD

Rezolute, Inc. (NASDAQ:RZLT) Given Consensus Rating of "Moderate Buy" by Analysts

September 13, 2026 | marketbeat.com

Rezolute: Initiating At Sell Despite Attempts To Rescue Ersodetug Following sunRIZE Upset

September 10, 2026 | seekingalpha.com

Rezolute Says FDA Still Reviewing Ersodetug Data From Phase 3 Congenital Hyperinsulinism Study

September 9, 2026 | finance.yahoo.com

Rezolute says late-stage trial data for lead asset remains under FDA review

September 9, 2026 | seekingalpha.com

Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint

September 9, 2026 | finance.yahoo.com

Rezolute, Inc. (RZLT) Interactive Stock Chart - Yahoo Finance

September 9, 2026 | finance.yahoo.com

Rezolute, Inc. (RZLT) Interactive Stock Chart - Yahoo Finance

September 9, 2026 | finance.yahoo.com

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

September 9, 2026 | globenewswire.com

Rezolute (RZLT) Projected to Release Earnings on Wednesday

September 9, 2026 | americanbankingnews.com

Rezolute (RZLT) Projected to Announce Earnings on Wednesday

September 9, 2026 | marketbeat.com

Rezolute to Participate in Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Rezolute Shares to Show Strength Towards Upcoming Ersodetug Catalysts, Wedbush Says

August 25, 2026 | finance.yahoo.com

Rezolute, Inc. $RZLT Shares Sold by Bank of America Corp DE

August 25, 2026 | marketbeat.com

Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Moderate Buy" by Brokerages

August 19, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Boston Scientific (BSX)

July 30, 2026 | theglobeandmail.com

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

July 21, 2026 | globenewswire.com

Rezolute Inc.

June 29, 2026 | marketwatch.com

FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

June 25, 2026 | stockhouse.com

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

June 17, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Vericel (VCEL)

June 12, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, CCCC, RZLT, and LRMR Company Descriptions

C4 Therapeutics NASDAQ:CCCC

$3.41 -0.04 (-1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$3.48 +0.06 (+1.91%)

As of 06:20 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Coya Therapeutics NASDAQ:COYA

$4.76 +0.30 (+6.73%)

Closing price 04:00 PM Eastern

Extended Trading

$4.76 0.00 (0.00%)

As of 04:10 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Larimar Therapeutics NASDAQ:LRMR

$3.80 -0.13 (-3.31%)

Closing price 04:00 PM Eastern

Extended Trading

$3.83 +0.03 (+0.89%)

As of 06:15 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Rezolute NASDAQ:RZLT

$3.95 -0.03 (-0.75%)

Closing price 04:00 PM Eastern

Extended Trading

$4.00 +0.05 (+1.39%)

As of 07:10 PM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COYA, CCCC, RZLT, and LRMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COYA, CCCC, RZLT, and LRMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COYA, CCCC, RZLT, and LRMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, CCCC, RZLT, and LRMR Company Descriptions

C4 Therapeutics NASDAQ:CCCC

Coya Therapeutics NASDAQ:COYA

Larimar Therapeutics NASDAQ:LRMR

Rezolute NASDAQ:RZLT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COYA, CCCC, RZLT, and LRMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COYA, CCCC, RZLT, and LRMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COYA, CCCC, RZLT, and LRMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, CCCC, RZLT, and LRMR Company Descriptions

C4 Therapeutics NASDAQ:CCCC

Coya Therapeutics NASDAQ:COYA

Larimar Therapeutics NASDAQ:LRMR

Rezolute NASDAQ:RZLT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools